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Background

Methods & Results

Conclusion

The biggest challenge in genomic
studies lies in data interpretation. With
this in mind, GA4K is employing an
advanced set of genomic tools to
uncover a greater number of candidate
variants in rare disease patients. These
tools
include
novel
sequencing
technologies to test beyond the exome
as well as machine-learning analysis
methods as presented here.

We combined two publicly available tools to aid with variant prioritization: Exomiser and AMELIE. Both tools (E/A) rely on structured
phenotyping (with HPO terms) but apply algorithms that explore different features of the variants/genes. Therefore, we hypothesized that
combining them would improve speed and accuracy of our analysis of genomic data.

The systematic use of combined E/A
ranking has proven consistent with
expert analysis in >80% of cases and can
be implemented as a ‘first pass’ tool to
expedite review of new data as it is
generated. In addition, E/A ranking
helps prioritize novel genes for further
studies. We foresee that these tools will
vastly speed up the analysis of our next
1000 cases.

Manual review of the combined top 50 ranked E/A candidate variants for each proband was carried out for the first 1000 cases.

About GA4K
The Genomic Answers for Kids study is
led by Dr. Tomi Pastinen and funded by
the Children’s Mercy Research Institute.
Our study aims to find diagnoses for
children who have undergone a lengthy
diagnostic odyssey with non-diagnostic
clinical testing, as well as to better
understand genetic disease as a whole.
We are a multidisciplinary team of
geneticists, bioinformaticians, genetic
counselors, laboratory technicians,
molecular biologists, and research
coordinators. For more information you
can contact us at GA4K@cmh.edu
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Figure 1 – Consistency between candidate variants ranked by E/A and full expert
analysis of the first 1000 GA4K rare disease cases.
Only 7% of conclusive candidates found by expert analysis were not ranked by E/A. In 6% of
cases, the mechanism of disease could not have been ranked (including: exonic deletions,
copy number changes, variants that are too frequent and filtered out). New candidates were
prioritized in 7% cases and are being further investigated; these include both known and
novel genes. “E/A + expert review both negative” samples are prioritized for further testing
with long-read sequencing, whole genome bisulphite sequencing and single cell analysis.

Figure 2 – Diagnostic rates from combined E/A and
expert review.
To date, 919 of 1000 cases have been reviewed in
depth with a diagnostic rate of 23.4% (n=215). An
additional 35.3% have a compelling variant of
uncertain significance in either an established or novel
gene. Further, 5.8% of cases have a single variant in a
known autosomal recessive disease gene.

Affiliations:
1) Genomic Medicine Center, Children’s Mercy Hospital
2) Department of Pathology and Laboratory Medicine,
Children’s Mercy Hospital
3) University of Missouri-Kansas City School of
Medicine
4) Department of Genetics, Children’s Mercy Hospital
https://www.childrensmercy.org/genomicanswers/

